The combination of the NK cell-activating interleukin IL-15 and therapeutic antibodies, which engaged the co-stimulatory receptor CD40, improved anti-tumor responses in Panc02 or KPC mouse tumor models [105]. This evidence concerns the gene IL15 and neoplasm.